Influence of vitamin D and retinoids on the gammacarboxylation of osteocalcin in human osteosarcoma MG63 cells.
Osteocalcin (OC) is a bone matrix protein, synthesized by osteoblasts, which contains three residues of gammacarboxyglutamic acid (GLA). A fraction of circulating OC, which is not fully carboxylated and does not bind to hydroxyapatite, is called undercarboxylated OC (ucOC). In elderly institutionalized women, we have shown an increase of circulating ucOC level which may result not only from vitamin K deficiency but also from vitamin D deficiency (Szulc et al., J Clin Invest 91:1769; 1993). This intriguing finding prompted us to study the effect of vitamin D on the secretion of ucOC by osteoblastic cells in vitro in the presence of warfarin, an inhibitor of gammacarboxylation of GLA-containing proteins. The potential influence of retinoic acid (RA) was also studied, because its mechanism of action involves pathways that are similar to vitamin D. In the presence of warfarin (0.05 microg/mL), 1alpha,25(OH)2D (10(-8)-10(-6) mol/L) decreased dose dependently ucOC secretion by human osteosarcoma MG63 cells (from 3.87 +/- 0.96 to 2.12 +/- 0.13 ng/10(6) cells). When expressed as a fraction of total OC, secretion ucOC decreased from 47.4 +/- 1.4% to 24.8 +/- 3.2% in the MG63 cells. The secretion of total OC was stimulated by RA and by Ro 13-7410, which is a specific ligand of retinoic acid receptor (RAR), but not by 9-cis retinoic acid (9-cisRA), which is a physiologic ligand of retinoid X receptor (RXR). RA and Ro 13-7410 decreased ucOC secretion and ucOC% in warfarin-treated MG63 cells (RA: from 50.4 +/- 13.3% to 13.5 +/- 2.8%; Ro 13-7410: from 28.4 +/- 8.2% to 11.3 +/- 8.4%). 9-cisRA had no effect on OC gammacarboxylation. These results show that vitamin D, RA, and Ro 13-7410, but not 9-cisRA, may modify the gammacarboxylation of OC in human MG63 cells.
Szulc
P
P
INSERM, Hôpital Edouard Herriot, Lyon, France.
Delmas
P D
PD
D000818:Animals; D001565:Benzoates / Q000494:pharmacology; D002264:Carboxylic Acids / Q000378:metabolism*; D002417:Cattle; D006801:Humans; D015675:Osteocalcin / Q000187:drug effects* / Q000378:metabolism; D012516:Osteosarcoma / Q000378:metabolism*; D012176:Retinoids / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014807:Vitamin D / Q000494:pharmacology*; D014859:Warfarin / Q000494:pharmacology
D001565:Benzoates; D002264:Carboxylic Acids; D012176:Retinoids; D015675:Osteocalcin; D014807:Vitamin D; D014212:Tretinoin; D014859:Warfarin; C038864:4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid